Byrd JB, Turcu AF, Auchus RJ. Primary aldosteronism. Circulation. 2018;138(8):823–35.
CAS
PubMed
PubMed Central
Google Scholar
Funder JW, Carey RM, Mantero F, Murad MH, Reincke M, Shibata H, et al. The management of primary aldosteronism: case detection, diagnosis, and treatment: an endocrine society clinical practice guideline. J Clin Endocrinol Metab. 2016;101(5):1889–916.
CAS
PubMed
Google Scholar
Douma S, Petidis K, Doumas M, Papaefthimiou P, Triantafyllou A, Kartali N, et al. Prevalence of primary hyperaldosteronism in resistant hypertension: a retrospective observational study. Lancet. 2008;371(9628):1921–6.
CAS
PubMed
Google Scholar
Monticone S, D'Ascenzo F, Moretti C, Williams TA, Veglio F, Gaita F, et al. Cardiovascular events and target organ damage in primary aldosteronism compared with essential hypertension: a systematic review and meta-analysis. Lancet Diabetes Endocrinol. 2018;6(1):41–50.
CAS
Google Scholar
Monticone S, Burrello J, Tizzani D, Bertello C, Viola A, Buffolo F, et al. Prevalence and clinical manifestations of primary aldosteronism encountered in primary care practice. J Am Coll Cardiol. 2017;69(14):1811–20.
PubMed
Google Scholar
Hung C-S, Sung S-H, Liao C-W, Pan C-T, Chang C-C, Chen Z-W, et al. Aldosterone induces vascular damage. Hypertension. 2019;74(3):623–9.
CAS
PubMed
Google Scholar
Luther JM. Aldosterone in vascular and metabolic dysfunction. Curr Opin Nephrol Hypertens. 2016;25(1):16–21.
CAS
PubMed
PubMed Central
Google Scholar
Mosso L, Carvajal C, González A, Barraza A, Avila F, Montero J, et al. Primary aldosteronism and hypertensive disease. Hypertension. 2003;42(2):161–5.
CAS
PubMed
Google Scholar
Reincke M, Fischer E, Gerum S, Merkle K, Schulz S, Pallauf A, et al. Observational study mortality in treated primary aldosteronism: the german conn’s registry. Hypertension. 2012;60(3):618–24.
CAS
PubMed
Google Scholar
Rossi GP. Primary aldosteronism: Jacc state-of-the-art review. J Am Coll Cardiol. 2019;74(22):2799–811.
CAS
PubMed
Google Scholar
Yan Y, Wang C, Lu Y, Gong H, Wu Z, Ma X, et al. Mineralocorticoid receptor antagonism protects the aorta from vascular smooth muscle cell proliferation and collagen deposition in a rat model of adrenal aldosterone-producing adenoma. J Physiol Biochem. 2018;74(1):17–24.
CAS
PubMed
Google Scholar
Zavatta G, Di Dalmazi G, Pizzi C, Bracchetti G, Mosconi C, Balacchi C, et al. Larger ascending aorta in primary aldosteronism: a 3-year prospective evaluation of adrenalectomy vs. Med Treatment Endocrine. 2019;63(3):470–5.
CAS
Google Scholar
Nienaber CA, Clough RE, Sakalihasan N, Suzuki T, Gibbs R, Mussa F, et al. Aortic dissection. Nat Rev Dis Primers. 2016;2:16053.
PubMed
Google Scholar
Shimizu A, Aoi W, Akahoshi M, Utsunomiya T, Doi Y, Suzuki S, et al. Elevation of plasma renin activity during pregnancy and rupture of a dissecting aortic aneurysm in a patient with primary aldosteronism. Jpn Heart J. 1983;24(6):995–1006.
CAS
PubMed
Google Scholar
Lam K-Y, Lo C-Y. The clinicopathologic significance of unilateral adrenal cortical hyperplasia: report of an unusual case and a review of the literature. Endocr Pathol. 1999;10(3):243–9.
PubMed
Google Scholar
Safi AM, Kwan T, Afflu E, Alam M, Anderson JE, Clark LT. Coronary artery aneurysms, aortic dissection, and hypertension secondary to primary aldosteronism: a rare triad. A case report. Angiology. 1999;50(6):503–8.
CAS
PubMed
Google Scholar
Ahmed SH, Husain NM, Khawaja SN, Massey CV, Pettyjohn FS. Is primary hyperaldosteronism a risk factor for aortic dissection? Cardiology. 2007;108(1):48–50.
PubMed
Google Scholar
Harvey KL, Riga C, Oconnor M, Hamady M, Chapman N, Gibbs RGJ. A rare case of aortic dissection and primary hyperaldosteronism. Ejves Extra. 2010;20(3):546.
Google Scholar
Hirai H, Shibata T, Sasaki Y, Fujii H, Kubo S, Suehiro S. Simultaneous surgery for chronic aortic dissection and adrenal adenoma with primary aldosteronism. Gen Thorac Cardiovasc Surg. 2010;58(5):235–8.
PubMed
Google Scholar
Shahrrava A, Moinuddin S, Boddu P, Shah R. A case of glucocorticoid remediable aldosteronism and thoracoabdominal aneurysms. Case Rep Endocrinol 2016, 2016:2017571.
Bossone E, LaBounty TM, Eagle KA. Acute aortic syndromes: Diagnosis and management, an update. Eur Heart J. 2018;39(9):739–49d.
PubMed
Google Scholar
Leibovitz E, Ebrahimian T, Paradis P, Schiffrin EL. Aldosterone induces arterial stiffness in absence of oxidative stress and endothelial dysfunction. J Hypertens. 2009;27(11):2192–200.
CAS
PubMed
Google Scholar
Kasal DA, Barhoumi T, Li MW, Yamamoto N, Zdanovich E, Rehman A, et al. T regulatory lymphocytes prevent aldosterone-induced vascular injury. Hypertension. 2012;59(2):324–30.
CAS
PubMed
Google Scholar
Bruder-Nascimento T, Ferreira NS, Zanotto CZ, Ramalho F, Pequeno IO, Olivon VC, et al. Nlrp3 inflammasome mediates aldosterone-induced vascular damage. Circulation. 2016;134(23):1866–80.
CAS
PubMed
Google Scholar
Moss ME, Jaffe IZ. Mineralocorticoid receptors in the pathophysiology of vascular inflammation and atherosclerosis. Front Endocrinol. 2015;6:153.
Google Scholar
Pu Q, Neves MF, Virdis A, Touyz RM, Schiffrin EL. Endothelin antagonism on aldosterone-induced oxidative stress and vascular remodeling. Hypertension. 2003;42(1):49–55.
CAS
PubMed
Google Scholar
Chrissobolis S. Vascular consequences of aldosterone excess and mineralocorticoid receptor antagonism. Curr Hypertens Rev. 2017;13(1):46–56.
CAS
PubMed
Google Scholar
Virdis A, Neves MF, Amiri F, Viel E, Touyz RM, Schiffrin EL. Spironolactone improves angiotensin-induced vascular changes and oxidative stress. Hypertension. 2002;40(4):504–10.
CAS
PubMed
Google Scholar
Park JB, Schiffrin EL. Et(a) receptor antagonist prevents blood pressure elevation and vascular remodeling in aldosterone-infused rats. Hypertension. 2001;37(6):1444–9.
CAS
PubMed
Google Scholar
Rickard AJ, Morgan J, Chrissobolis S, Miller AA, Sobey CG, Young MJ. Endothelial cell mineralocorticoid receptors regulate deoxycorticosterone/salt-mediated cardiac remodeling and vascular reactivity but not blood pressure. Hypertension. 2014;63(5):1033–40.
CAS
PubMed
Google Scholar
Pruthi D, McCurley A, Aronovitz M, Galayda C, Karumanchi SA, Jaffe IZ. Aldosterone promotes vascular remodeling by direct effects on smooth muscle cell mineralocorticoid receptors. Arterioscler Thromb Vasc Biol. 2014;34(2):355–64.
CAS
PubMed
Google Scholar
Rigsby CS, Pollock DM, Dorrance AM. Spironolactone improves structure and increases tone in the cerebral vasculature of male spontaneously hypertensive stroke-prone rats. Microvasc Res. 2007;73(3):198–205.
CAS
PubMed
PubMed Central
Google Scholar
Rigsby CS, Ergul A, Portik Dobos V, Pollock DM, Dorrance AM. Effects of spironolactone on cerebral vessel structure in rats with sustained hypertension. Am J Hypertens. 2011;24(6):708–15.
CAS
PubMed
PubMed Central
Google Scholar
Rajagopalan S, Duquaine D, King S, Pitt B, Patel P. Mineralocorticoid receptor antagonism in experimental atherosclerosis. Circulation. 2002;105(18):2212–6.
CAS
PubMed
Google Scholar
Raz-Pasteur A, Gamliel-Lazarovich A, Coleman R, Keidar S. Eplerenone reduced lesion size in early but not advanced atherosclerosis in apolipoprotein e-deficient mice. J Cardiovasc Pharmacol. 2012;60(6):508–12.
CAS
PubMed
Google Scholar